Preclinical studies have demonstrated that activation of plasmacytoid dendritic cells expressing TLR9 by SD-101 potentiates T cell infiltration into the tumor microenvironment, thereby increasing tumor cell destruction [22, 23]. The gene discussed is TLR9; the disease is neoplasm.